Monitoring antiretroviral activity using ICDp24 and CD4 counts in HIV infection.
The fluctuations of HIV-1 p24 antigen concentration have been monitored in the follow-up of 118 subjects in different clinical stages and compared to their CD4 cell count; 104 patients received antiretroviral therapy. Persistent (65%) or sporadic (28%) antigenaemia has been detected in most patients in different clinical stages. The variations of the p24 Ag level are significantly correlated with the CD4 cell count and therapy administration (P = 0.0001). In patients with relatively conserved immune function (CDC II and III), antiretroviral therapy shows the best efficacy and can be efficiently monitored by p24 and CD4 surrogate markers. The data here suggest that although the informative value of p24 Ag is not representative of an AIDS-defining event, it can be used as a short-term and relatively inexpensive virological marker of antiviral activity in vivo, to support the routine management of patients.
Lillo
F B
FB
Laboratory of Virology and Infectious Disease Clinic, AIDS Centre San Luigi IRCCS HSR, Milano, Italy.
Maillard
M
M
Saracco
A
A
Varnier
O E
OE
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000627:therapeutic use; D005500:Follow-Up Studies; D016655:HIV Core Protein p24 / Q000097:blood*; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D016655:HIV Core Protein p24; D015215:Zidovudine; D016049:Didanosine